-
1 Comment
Sinco Pharmaceuticals Holdings Limited is currently in a long term uptrend where the price is trading 41.6% above its 200 day moving average.
From a valuation standpoint, the stock is 90.6% cheaper than other stocks from the Communication Services sector with a price to sales ratio of 0.7.
Sinco Pharmaceuticals Holdings Limited's total revenue rose by 120.5% to $1B since the same quarter in the previous year.
Its net income has increased by 1014.1% to $86M since the same quarter in the previous year.
Finally, its free cash flow grew by 5666.4% to $113M since the same quarter in the previous year.
Based on the above factors, Sinco Pharmaceuticals Holdings Limited gets an overall score of 5/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| ISIN | KYG8154Y1052 |
| Sector | Healthcare |
| Industry | Medical Distribution |
| PE Ratio | 9.25 |
|---|---|
| Target Price | None |
| Dividend Yield | 1.0% |
| Beta | 1.03 |
| Market Cap | 376M |
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. It offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. The company also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases comprising alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, an oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, it is involved in the research, development, and sale of pharmaceutical products; provision of warehouse facilities for pharmaceutical products; research and manufacturing of aesthetic medicine; international trade activities; consultation services for medical and biological technology; market promotion; and medical beauty services. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited operates as a subsidiary of Risun Investment Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6833.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
